<DOC>
	<DOCNO>NCT01205776</DOCNO>
	<brief_summary>To establish safety efficacy commercially approve XIENCE Family Stent System ( inclusive XIENCE PRIME , XIENCE V , XIENCE Xpedition XIENCE PRO [ use outside United States [ OUS ] ] ) subject unprotected leave main coronary artery disease compare coronary artery bypass graft surgery .</brief_summary>
	<brief_title>EXCEL Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<criteria>* Inclusion criterion RCT : Unprotected leave main coronary artery ( ULMCA ) disease angiographic diameter stenosis ( DS ) ≥70 % require revascularization , ULMCA disease agniographic DS &gt; =50 % &lt; 70 % require revascularization , one follow present : Noninvasive evidence ischemia referable hemodynamically significant leave main lesion ( large area ischemia LAD LCX territory , either LAD LCX territory absence obstructive coronary artery disease explain LAD LCX defect ) , stressinduced hypotension stressinduced fall LVEF , stressinduced transient ischemic dilatation leave ventricle stressinduced thallium/technetiumlung uptake , and/or IVUS minimum lumen area ( MLA ) &lt; = 6.0mm2 , and/or Fractional Flow Reserve ( FFR ) &lt; =0.80 Left Main Equivalent Disease Clinical anatomic eligibility PCI CABG Silent ischemia , stable angina , unstable angina recent MI Ability sign inform consent comply study procedure include followup least three year * Clinical exclusion criterion : Prior PCI leave main trunk time prior randomization Prior PCI coronary artery lesion within one year prior randomization Prior CABG time prior randomization Need concomitant cardiac surgery CABG , intent subject randomize surgery , cardiac surgical procedure isolate CABG perform CKMB great local laboratory upper limit normal recent MI CKMB still elevate Subjects unable tolerate , obtain comply dual antiplatelet therapy least one year Subjects require may require additional surgery within one year The presence clinical condition ( ) lead participate interventional cardiologist believe clinical equipoise present The presence clinical condition ( ) lead participate cardiac surgeon believe clinical equipoise present Pregnancy intention become pregnant Non cardiac comorbidities life expectancy le 3 year Other investigational drug device study reach primary endpoint Vulnerable population judgment investigator unable give Informed Consent reason incapacity , immaturity , adverse personal circumstance lack autonomy . This may include : Individuals mental disability , person nurse home , child , impoverished person , person emergency situation , homeless person , nomad , refugee , permanently incapable give informed consent . Vulnerable population also may include member group hierarchical structure university student , subordinate hospital laboratory personnel , employee Sponsor , member arm force , person keep detention Angiographic exclusion criterion : Left main diameter stenosis &lt; 50 % SYNTAX score ≥33 Left main reference vessel diameter &lt; 2.25 mm &gt; 4.25 mm The presence specific coronary lesion characteristic cardiac condition ( ) lead participate interventional cardiologist believe clinical equipoise present The presence specific coronary lesion characteristic cardiac condition ( ) lead participate cardiac surgeon believe clinical equipoise present</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Stents</keyword>
	<keyword>Unprotected Left Main Coronary Artery Disease</keyword>
	<keyword>Coronary artery bypass graft surgery</keyword>
</DOC>